Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 4, 2022- Two durable partial responses in checkpoint inhibitor-naive nasopharyngeal carcinoma and uveal melanoma patients in dose escalation of INBRX-106 in combination with Keytruda®
-
Dec 1, 2021- Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma
-
Nov 3, 2021
-
Jun 21, 2021- Median progression-free survival (PFS) of 7.6 months and disease control rate of 87.5% observed in conventional chondrosarcoma patients in Phase 1
